ID

34401

Beschreibung

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib; ODM derived from: https://clinicaltrials.gov/show/NCT01514448

Link

https://clinicaltrials.gov/show/NCT01514448

Stichworte

  1. 17.01.19 17.01.19 -
Rechteinhaber

see on clinicaltrials.gov

Hochgeladen am

17. Januar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
Beschreibung

ID.1

Datentyp

boolean

progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.
Beschreibung

ID.2

Datentyp

boolean

patients scheduled for treatment with everolimus.
Beschreibung

ID.3

Datentyp

boolean

patients with at least one measurable lesion at baseline.
Beschreibung

ID.4

Datentyp

boolean

Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.
Beschreibung

ID.5

Datentyp

boolean

patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).
Beschreibung

ID.6

Datentyp

boolean

patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
Beschreibung

ID.7

Datentyp

boolean

patients unwilling or unable to comply with the protocol.
Beschreibung

ID.8

Datentyp

boolean

other protocol-defined inclusion/exclusion criteria may apply.
Beschreibung

ID.9

Datentyp

boolean

Ähnliche Modelle

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
boolean
ID.2
Item
progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.
boolean
ID.3
Item
patients scheduled for treatment with everolimus.
boolean
ID.4
Item
patients with at least one measurable lesion at baseline.
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.
boolean
ID.6
Item
patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).
boolean
ID.7
Item
patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
boolean
ID.8
Item
patients unwilling or unable to comply with the protocol.
boolean
ID.9
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video